Diamyd reports successes in Q4
In her comments in today’s year-end report, Elisabeth Lindner, President and CEO of Diamyd Medical, reports that in the last year Diamyd has come ever closer to realizing its vision of being able to prevent and cure the autoimmune form of diabetes in the future.The most recent quarter has seen significant success in the American Phase III study of the Diamyd® diabetes vaccine, since the US FDA approved the inclusion of children aged 10 and above. The number of clinics in the US will now be gradually tripled to over forty, and an agreement has been signed with patient recruitment firm